1. Market Research
  2. > Biotechnology Market Trends
  3. > Oncolytics Biotech Inc. – Product Pipeline Review – 2013

Oncolytics Biotech Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 84 pages

Oncolytics Biotech Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Oncolytics Biotech Inc. - Product Pipeline Review - 2013” provides data on the Oncolytics Biotech Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Oncolytics Biotech Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Oncolytics Biotech Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oncolytics Biotech Inc. - Brief Oncolytics Biotech Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oncolytics Biotech Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oncolytics Biotech Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oncolytics Biotech Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oncolytics Biotech Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oncolytics Biotech Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oncolytics Biotech Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Oncolytics Biotech Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Oncolytics Biotech Inc. and identify potential opportunities in those areas.

Table Of Contents

Oncolytics Biotech Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Oncolytics Biotech Inc. Snapshot 6
Oncolytics Biotech Inc. Overview 6
Key Information 6
Key Facts 6
Oncolytics Biotech Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Oncolytics Biotech Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Oncolytics Biotech Inc. - Pipeline Products Glance 13
Oncolytics Biotech Inc. - Late Stage Pipeline 13
Phase III Products/Combination Treatment Modalities 13
Oncolytics Biotech Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Oncolytics Biotech Inc. - Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
Oncolytics Biotech Inc. - Drug Profiles 17
pelareorep 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
pelareorep + [carboplatin] + [paclitaxel] 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
pelareorep + [cyclophosphamide] 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Reolysin + [cisplatin] + Radiation Therapy 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Reolysin + [docetaxel] 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Reolysin + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] 30
Product Description 30
Mechanism of Action 30
RandD Progress 31
Reolysin + [gemcitabine hydrochloride] 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Reolysin + [paclitaxel] 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Oncolytics Biotech Inc. - Pipeline Products by Route of Administration 36
Oncolytics Biotech Inc. - Recent Pipeline Updates 37
Oncolytics Biotech Inc. - Company Statement 44
Oncolytics Biotech Inc. - Locations And Subsidiaries 47
Head Office 47
Other Locations and Subsidiaries 47
Oncolytics Biotech Inc., Recent Developments 48
Oncolytics Biotech Inc.- Press Release 48
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer 48
Mar 05, 2013: Oncolytics Biotech Completes Patient Enrollment In US Phase II Study Of Reolysin In Non-small Cell Lung Cancer 48
Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung 49
Jan 28, 2013: Oncolytics Biotech Announces Presentation Of Positive Reolysin Clinical Trial Data At ASCO Gastrointestinal Cancers Symposium 49
Dec 01, 2010: Oncolytics Announces Start Of Enrollment In Randomized Phase II Ovarian Cancer Study 50
Nov 29, 2010: Oncolytics Announces Publication Of Phase I Clinical Trial Results Examining Combination Of REOLYSIN And Docetaxel In Clinical Cancer Research 51
Nov 18, 2010: Oncolytics Announces Phase I Study In Pediatric Patients With Relapsed Or Refractory Solid Tumors To Be Conducted By Children's Oncology Group 52
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group 52
Jul 19, 2010: Oncolytics Receives No Objection Letter From Health Canada To Conduct Phase III Trial Of REOLYSIN In Head And Neck Cancers 53
Jun 07, 2010: Oncolytics Collaborators Present Positive Updated UK Phase I/II Trial Results In Advanced Solid Cancers At ASCO Annual Meeting 54
Jun 01, 2010: Oncolytics Receives Approval From Belgium FAMHP To Conduct Phase III Trial For REOLYSIN In Head And Neck Cancers 55
May 26, 2010: Oncolytics Biotech Initiates Enrolment In US Phase II Pancreatic Cancer Clinical Trial 55
May 25, 2010: Oncolytics Biotech Opens Enrollment In Phase III Trial For REOLYSIN In Head And Neck Cancers 56
May 21, 2010: Oncolytics Biotech Announces Reovirus Research To Be Presented At ASCO Annual Meeting 57
May 19, 2010: Oncolytics Initiates Phase I Colorectal Cancer Study Of REOLYSIN In Combination With FOLFIRI 58
May 18, 2010: Oncolytics Announces Publication Of Phase I Clinical Trial Results In Clinical Cancer Research 59
Apr 23, 2010: Oncolytics Completes Patient Enrollment In Phase I Portion Of US Phase I/II Recurrent Malignant Gliomas Clinical Trial With REOLYSIN 59
Apr 08, 2010: Oncolytics Announces Publication Of Preclinical Research On Combination Of Antiangiogenic Cancer Therapy With Oncolytic Virotherapy 60
Mar 30, 2010: Oncolytics Announces Start Of Enrollment In US Phase II SCC Lung Cancer Trial 61
Mar 30, 2010: Oncolytics Starts Enrollment In US Phase II SCC Lung Cancer Trial 61
Feb 16, 2010: Oncolytics Biotech Receives Approval From The U.K. MHRA To Conduct Phase II Trial For REOLYSIN In Head And Neck Cancers 62
Feb 16, 2010: Oncolytics Receives Approval From UK MHRA To Conduct Phase III Trial For REOLYSIN In Head And Neck Cancers 63
Financial Deals Landscape 65
Oncolytics Biotech Inc., Deals Summary 65
Oncolytics Biotech Inc., Pharmaceuticals and Healthcare, Deal Details 66
Equity Offering 66
Oncolytics Biotech Completes Public Offering Of Common Stock For $32 Million 66
Oncolytics Biotech Completes Private Placement Of Shares For $21 Million 68
Oncolytics Biotech Raises $7.87 Million Upon Exercise Of Warrants 70
Oncolytics Biotech Raises $6.8 Million Upon Exercise Of Warrants 71
Oncolytics Biotech Completes Private Placement Of $28 Million 72
Oncolytics Biotech Announces Exercise Of Underwriter's Allotment Option 74
Oncolytics Biotech Completes Public Offering Of $6 Million 76
Oncolytics Biotech Completes Public Offering Of $3 Million 78
Oncolytics Biotech Completes Public Offering Of $12 Million 80
Acquisition 82
Oncolytics Acquires 10% Stake In British Canadian Biosciences 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84



List of Tables

Oncolytics Biotech Inc., Key Information 6
Oncolytics Biotech Inc., Key Facts 6
Oncolytics Biotech Inc. - Pipeline by Indication, 2013 8
Oncolytics Biotech Inc. - Pipeline by Stage of Development, 2013 10
Oncolytics Biotech Inc. - Monotherapy Products in Pipeline, 2013 11
Oncolytics Biotech Inc. - Combination Treatment Modalities in Pipeline, 2013 12
Oncolytics Biotech Inc. - Phase III, 2013 13
Oncolytics Biotech Inc. - Phase II, 2013 14
Oncolytics Biotech Inc. - Phase I, 2013 15
Oncolytics Biotech Inc. - Pre-Clinical, 2013 16
Oncolytics Biotech Inc. - Pipeline By Route of Administration, 2013 36
Oncolytics Biotech Inc. - Recent Pipeline Updates, 2013 37
Oncolytics Biotech Inc., Subsidiaries 47
Oncolytics Biotech Inc., Deals Summary 65
Oncolytics Biotech Completes Public Offering Of Common Stock For $32 Million 66
Oncolytics Biotech Completes Private Placement Of Shares For $21 Million 68
Oncolytics Biotech Raises $7.87 Million Upon Exercise Of Warrants 70
Oncolytics Biotech Raises $6.8 Million Upon Exercise Of Warrants 71
Oncolytics Biotech Completes Private Placement Of $28 Million 72
Oncolytics Biotech Announces Exercise Of Underwriter's Allotment Option 74
Oncolytics Biotech Completes Public Offering Of $6 Million 76
Oncolytics Biotech Completes Public Offering Of $3 Million 78
Oncolytics Biotech Completes Public Offering Of $12 Million 80
Oncolytics Acquires 10% Stake In British Canadian Biosciences 82



List of Figures

Oncolytics Biotech Inc. - Pipeline by Indication, 2013 8
Oncolytics Biotech Inc. - Pipeline by Stage of Development, 2013 10
Oncolytics Biotech Inc. - Monotherapy Products in Pipeline, 2013 11
Oncolytics Biotech Inc. - Combination Treatment Modalities in Pipeline, 2013 12
Oncolytics Biotech Inc. - Pipeline By Route of Administration, 2013 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.